NCT06203600 2026-03-17
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca